Nasus Pharma is trading 10.66% up at $3.84 in after-hours trading, likely driven by the positive first-half 2026 financial results released on August 17, 2026. - The company reported cash, cash equivalents and short-term deposits rising to $11.8 million as of June 30, 2026, from approximately $4.3 million at year-end 2025. - Total assets more than doubled to $12.4 million. - News of CFO Eyal Rubin's departure was also announced today, though it is less likely to be the primary driver for such a significant positive price movement.